SPARVASC
SPARsentan treatment in VASCulitis (SPARVASC) – Endothelin receptor antagonism to reduce cardiovascular risk in ANCA-associated vasculitis. A double blind trial investigating the effects of sparsentan on blood pressure in patients with vasculitis.